DJIA 17,416.85 225.48 1.31%
NASDAQ 4,683.41 45.41 0.98%
S&P 500 2,021.25 19.09 0.95%
market minute promo

Epizyme (NASDAQ: EPZM)

20.54 -0.57 (-2.70%)

Quote as of

company name or ticker

Recent Quotes

EPZM $20.54 -2.70%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $21.30
Previous Close $21.11
Daily Range $20.23 - $21.30
52-Week Range $16.51 - $40.98
Market Cap $701.7M
P/E Ratio 527.75
Dividend (Yield) $0.00 (0.0%)
Volume 136,884
Average Daily Volume 327,573
Current FY EPS -$1.74



Epizyme (EPZM) Description

Epizyme Inc is a clinical stage biopharmaceutical company that discovers develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers. Website:

News & Commentary

5 Predictions for Biotechnology Stocks in 2015

Celgene Corp, Alkermes, GW Pharmaceuticals, Gilead Sciences, and Hospira should all be on investors radar in 2015.

Primecap Exceeds 5% Threshold In Shutterfly, 3 Other Companies

Epizyme: The Ugly Duckling Of The 2014 Biotech Rally?

Commit To Purchase Epizyme At $15, Earn 11.5% Annualized Using Options

Epizyme: Shares Oversold On Mixed Data From Early Studies

RSI Alert: Epizyme (EPZM) Now Oversold

3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't

Gilead Sciences, Celgene, and Biogen all have rock-solid financials, but none are likely to pay a dividend anytime soon.

Epizyme Gains on Positive Phase I Data on EPZ-6438 - Analyst Blog

Midday Losers From November 6: Qualcomm, Genworth Financial, Epizyme, Nationstar Mortgage

Epizyme (EPZM) CEO Robert Gould on Q3 2014 Results - Earnings Call Transcript

See More EPZM News...